Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human...

Area of Science:

• Neuroscience
• Psychiatry
• Biochemistry

Background:

• Major depressive disorder (MDD) affects millions, with up to 20% experiencing treatment-resistant depression.
• Current antidepressants (SSRIs, MAOIs, TCAs) often fail due to limitations of the monoamine hypothesis.
• Emerging research suggests inflammation and the kynurenine pathway play a role in MDD pathophysiology.

Purpose of the Study:

• To review the role of the kynurenine pathway in the pathophysiology of depression.
• To explore novel therapeutic targets for major depressive disorder based on the kynurenine pathway.
• To synthesize findings from preclinical and clinical studies on kynurenine pathway modulators.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of research on tryptophan degradation and inflammatory mediators.
• Synthesis of evidence linking the kynurenine pathway to depression.

Main Results:

• Inflammation influences tryptophan degradation via the kynurenine pathway.
• This pathway is implicated in the development and persistence of depressive symptoms.
• Specific enzymes and metabolites within the kynurenine pathway represent potential therapeutic targets.

Conclusions:

• The kynurenine pathway offers a promising new avenue for understanding and treating major depressive disorder.
• Modulating this pathway could lead to more effective antidepressants for treatment-resistant cases.
• Further research into kynurenine pathway interventions is warranted.